Matrix Capital Management
VC Fund
Waltham, United States
Matrix Capital Management ("Matrix") is an investment management firm overseeing a focused portfolio of carefully selected public and private investments. Established in 1999, Matrix Capital was co-founded by David Goel and is headquartered in Waltham, Massachusetts. Matrix has delivered attractive, long-term risk-adjusted returns througha concentrated portfolio of high-conviction investments in U.S. companies focused on semiconductors, software, generative artificial intelligence, machine learning, neural networks, and the technology convergence in life sciences. Prior to co-founding Matrix, Managing General Partner David Goel was a senior technology investor at Julian Robertson’s Tiger Management.
- Total investments:
- 42
- Last investment:
- Lead investor:
- 52%
Last updated:
For AI agents: llms.txt
Industries Matrix Capital Management invests in
Stages Matrix Capital Management invests in
Countries Matrix Capital Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Paul J. Ferri
|
|||
Alan Colowick
|
|||
David Goel
|
|||
TJ Crutchfield, Jr.
|
|||
1 more contact available
Investment Focus
Industry
- Biotechnology 17 (40%)
- Health Care 16 (38%)
- Life Science 4 (10%)
- Therapeutics 4 (10%)
- Pharmaceutical 4 (10%)
Stage
- Series B 10 (24%)
- Series C 10 (24%)
- Series A 9 (21%)
- Series D 4 (10%)
- Seed 2 (5%)
Country
- United States 26 (62%)
- New Zealand 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Paul J. Ferri
Co-Founder
|
Co-Founder | Total investments: 10 | Find email | |
|
Alan Colowick
Managing Director
|
Managing Director | Total investments: 7 | Find email | |
|
David Goel
Founder & Managing General Partner
|
Founder & Managing General Partner | Total investments: 3 | Find email | |
|
TJ Crutchfield, Jr.
Head of the Office of the General Partner at Matrix Capital Management Company, L.P.
|
Head of the Office of the General Partner at Matrix Capital Management Company, L.P. | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Anumana
|
Anumana develops AI algorithms that analyze ECG data to support early diagnosis of cardiovascular conditions. The company focuses on enhancing cardiac care through innovative technology, providing tools that assist healthcare professionals in identifying potential heart issues. Anumana's platform extends beyond diagnostics, aiming to improvepatient outcomes throughout the entire continuum of cardiovascular care, including perioperative and acute settings. By utilizing machine learning techniques, Anumana aims to refine screening processes, making it easier for clinicians to detect heart diseases and intervene promptly. This approach contributes to more efficient healthcare delivery and better management of cardiovascular health. | Series C / Apr 24, 2025 | |
Maze Therapeutics
|
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.andits also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases. | $115M / Series D / Dec 03, 2024 | |
Rivos
|
Rivos is a high-performance RISC-V system startup targeting integrated system solutions for enterprises. | $250M / Series A / Apr 16, 2024 | |
Alumis
|
Alumis is a precision medicines company looking to eliminate the “all-comers” approach that is seen with today’s treatments for people with autoimmune disease. Even with the innovation of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of theirdisease without life-impacting side effects. Esker leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease. | $259M / Series C / Mar 06, 2024 | |
ReCode Therapeutics
|
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and developfirst-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.The company was founded in 2015 and is based in Dallas, Texas. | $50M / Series B / Sep 19, 2023 | |
AltPep
|
AltPep Corp is a biomedical startup with a breakthrough approach for diagnosing and treating some of the world’s most intractable diseases: amyloid diseases. | $52.9M / Series B / Jun 22, 2023 | |
ElevateBio
|
ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines.The company creates a portfolio through partnerships with the world's innovative scientists and inventors as well as it created a centralized facility that integrates all the elementsthat translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases.Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017. | $401M / Series D / May 24, 2023 | |
ACELYRIN
|
ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients. | $300M / Series C / Sep 13, 2022 | |
Monod Bio
|
Monod Bio is a life sciences company developing biosensors for protein and other analyte detection. Its biosensor platform combines binding, transduction, and amplification to detect a range of target molecules. It utilizes recent advances in computational protein engineering to create highly modular bio-sensing nano switches that stimulate rapid,sensitive, and inexpensive analytical assays.Monod Bio was founded in 2021 and is headquartered in Seattle, Washington. | $25M / Seed / Aug 15, 2022 | |
|
ReCode Therapeutics
|
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and developfirst-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.The company was founded in 2015 and is based in Dallas, Texas. | $120M / Series B / Jun 29, 2022 | |
| See all 42 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Matrix Capital Management invest in?
Matrix Capital Management invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series B and Series C stage. Most of the 42 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Matrix Capital Management?
Public channels for Matrix Capital Management include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Matrix Capital Management?
The team at Matrix Capital Management includes Paul J. Ferri (Co-Founder), Alan Colowick (Managing Director) and David Goel (Founder & Managing General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
